Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | USP2 | O75604 | 1/20 | 0.56 |
| ▸ | HTT | P42858 | 2/20 | 0.55 |
| ▸ | SPHK1 | Q9NYA1 | 1/20 | 0.54 |
| ▸ | LPAR1 | Q92633 | 7/20 | 0.50 |
| ▸ | LPAR3 | Q9UBY5 | 7/20 | 0.50 |
| ▸ | LPAR2 | Q9HBW0 | 4/20 | 0.50 |
| ▸ | LPAR5 | Q9H1C0 | 4/20 | 0.47 |
| ▸ | CES2 | O00748 | 1/20 | 0.46 |
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
| ▸ | THRB | P10828 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
| ▸ | MAPT | P10636 | 1/20 | 0.44 |
| ▸ | LPAR6 | P43657 | 3/20 | 0.44 |
| ▸ | LPAR4 | Q99677 | 3/20 | 0.44 |
| ▸ | TLR2 | O60603 | 2/20 | 0.43 |
| ▸ | PLA2G2C | Q5R387 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16475717 | 1.00 | USP2 (0.56) | USP2HTTSPHK1LPAR1LPAR3 | |
| SCHEMBL28837480 | 0.92 | USP2 (0.46) | USP2HTTSPHK1LPAR1LPAR3 | |
| SCHEMBL10563161 | 0.89 | USP2 (0.56) | USP2HTTSPHK1LPAR1LPAR3 | |
| SCHEMBL10563880 | 0.89 | USP2 (0.56) | USP2HTTSPHK1LPAR1LPAR3 | |
| SCHEMBL10564965 | 0.89 | USP2 (0.56) | USP2HTTSPHK1LPAR1LPAR3 | |
| SCHEMBL7722110 | 0.89 | USP2 (0.56) | USP2HTTSPHK1LPAR1LPAR3 | |
| SCHEMBL10650853 | 0.89 | USP2 (0.56) | USP2HTTSPHK1LPAR1LPAR3 | |
| SCHEMBL10565916 | 0.89 | USP2 (0.56) | USP2HTTSPHK1LPAR1LPAR3 | |
| SCHEMBL7719370 | 0.89 | USP2 (0.56) | USP2HTTSPHK1LPAR1LPAR3 | |
| SCHEMBL10564916 | 0.89 | USP2 (0.56) | USP2HTTSPHK1LPAR1LPAR3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3202760-B1 | PEGYLATED LIPIDS AND THEIR USE FOR DRUG DELIVERY | ALNYLAM PHARMACEUTICALS INC (US) | 2019-08-21 | — | — | EP | disclosed |
| US-9999673-B2 | PEGylated lipids and their use for drug delivery | ALNYLAM PHARMACEUTICALS, INC. (US) | 2018-06-19 | — | — | US | disclosed |
| US-9999673-B2 | PEGylated lipids and their use for drug delivery | ALNYLAM PHARMACEUTICALS, INC. (US) | 2018-06-19 | — | — | US | disclosed |
| EP-3202760-A1 | PEGYLATED LIPIDS AND THEIR USE FOR DRUG DELIVERY | Alnylam Pharmaceuticals, Inc. (US) | 2017-08-09 | — | — | EP | disclosed |
| EP-2663548-B1 | PEGYLATED LIPIDS AND THEIR USE FOR DRUG DELIVERY | ALNYLAM PHARMACEUTICALS INC (US) | 2017-04-05 | — | — | EP | disclosed |
| US-20140200257-A1 | PEGYLATED LIPIDS AND THEIR USE FOR DRUG DELIVERY | ALNYLAM PHARMACEUTICALS, INC. (US) | 2014-07-17 | — | — | US | disclosed |
| US-20140200257-A1 | PEGYLATED LIPIDS AND THEIR USE FOR DRUG DELIVERY | ALNYLAM PHARMACEUTICALS, INC. (US) | 2014-07-17 | — | — | US | disclosed |
| EP-2663548-A1 | PEGYLATED LIPIDS AND THEIR USE FOR DRUG DELIVERY | Alnylam Pharmaceuticals, Inc. (US) | 2013-11-20 | — | — | EP | disclosed |
| WO-2012099755-A1 | PEGYLATED LIPIDS AND THEIR USE FOR DRUG DELIVERY | ALNYLAM PHARMACEUTICALS, INC. (US) | 2012-07-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140200257-A1 | PEGYLATED LIPIDS AND THEIR USE FOR DRUG DELIVERY | LIPG, EGFR, LDLR | USP2 823/4885HTT 2096/4885SPHK1 637/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.